ArticleJournal of clinical laboratory analysis2020
Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations.Frontiers in oncology · 2021Pooled it
- Integrated analysis of miR-15a-5p, miR-20a-5p, and miR-33b-3p identifies EGR2-associated biomarkers in multiple myeloma.BMC cancer · 2026Article
- Altered miRNA expression in the lesions of cutaneous leishmaniasis caused by L. major and L. tropica with insights into apoptosis regulation.Scientific reports · 2025Article
- A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma.SAGE open medicine · 2025Review
- The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility.British journal of biomedical science · 2025Review
- mMolecular neurobiology · 2024Article
- Review
- Mitochondria-associated programmed cell death: elucidating prognostic biomarkers, immune checkpoints, and therapeutic avenues in multiple myeloma.Frontiers in immunology · 2024Article
- Identifying the potential genes in alpha synuclein driving ferroptosis of Parkinson's disease.Scientific reports · 2023Article
- The role of microRNA-4723-5p regulated by c-myc in triple-negative breast cancer.Bioengineered · 2022Article
- MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease.Cancers · 2021Review
- Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis.Journal of bone oncology · 2020Review
- Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma (MM) is still an incurable hematological malignancy evolved from asymptomatic monoclonal gammopathy of undetermined significance (MGUS). New evidence suggests that circulating microRNAs (miRNAs) can serve as stable diagnostic biomarkers for MM and MUGS.
methodsSerum miRNAs in MM patients, MUGS patients, and healthy controls (HC) were performed by Agilent Bioanalyzer 2100. MicroRNAs in MM detected as promising biomarkers were validated by using quantitative real-time PCR (qRT-PCR). Receiver operator characteristic (ROC) curve and multivariate logistic analysis were used to evaluate the diagnostic value of miRNAs for MM and MUGS.
resultsIn microarray analysis, the top ten differential expressed miRNAs in MM included miR-134-5p, miR-107, miR-15a-5p, miR-5159-3p, miR-1914-3p, miR-4723-3p, miR-5588-3p, miR-6893-3p, miR-7106-3p, and miR-6722-5p. Three up-regulated miRNAs (miR-134-5p, miR-107, and miR-15a-5p) were further validated. The elevated expression levels of miR-134-5p, miR-107, and miR-15a-5p in qRT-PCR were increased consistent with microarray analysis. These miRNAs distinguished MM and MUGS from HC significantly. Multivariate logistic analysis showed combination miR-107, miR-15a-5p with Hb, the AUC was 0.954 (95% CI: 0.890-1.000), sensitivity of 91.3%, and specificity of 93.7% for distinguishing MM from MUGS.
conclusionsThese data demonstrate that miR-134-5p, miR-107, and miR-15a-5p are potential diagnostic biomarkers in MM and MUGS. Moreover, the combination miR-107 and miR-15a-5p with Hb can distinguish MM from MUGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.